nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—CYP2C19—Teniposide—lymphatic system cancer	0.204	0.296	CbGbCtD
Tolterodine—CYP2C9—Teniposide—lymphatic system cancer	0.17	0.246	CbGbCtD
Tolterodine—CYP3A4—Cytarabine—lymphatic system cancer	0.1	0.145	CbGbCtD
Tolterodine—CYP3A4—Teniposide—lymphatic system cancer	0.0988	0.143	CbGbCtD
Tolterodine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0691	0.1	CbGbCtD
Tolterodine—CYP3A4—Vincristine—lymphatic system cancer	0.0475	0.0689	CbGbCtD
Tolterodine—Dementia—Methotrexate—lymphatic system cancer	0.00608	0.0196	CcSEcCtD
Tolterodine—Vertigo—Mechlorethamine—lymphatic system cancer	0.0051	0.0165	CcSEcCtD
Tolterodine—Bronchitis—Fludarabine—lymphatic system cancer	0.00508	0.0164	CcSEcCtD
Tolterodine—Disorientation—Bleomycin—lymphatic system cancer	0.00501	0.0162	CcSEcCtD
Tolterodine—Dysuria—Fludarabine—lymphatic system cancer	0.00494	0.0159	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00491	0.0158	CcSEcCtD
Tolterodine—Abnormal vision—Carmustine—lymphatic system cancer	0.0047	0.0152	CcSEcCtD
Tolterodine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00464	0.0149	CcSEcCtD
Tolterodine—Infection—Mechlorethamine—lymphatic system cancer	0.00461	0.0149	CcSEcCtD
Tolterodine—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00458	0.0148	CcSEcCtD
Tolterodine—Flushing—Teniposide—lymphatic system cancer	0.00446	0.0144	CcSEcCtD
Tolterodine—Sinusitis—Fludarabine—lymphatic system cancer	0.00442	0.0142	CcSEcCtD
Tolterodine—Visual impairment—Fludarabine—lymphatic system cancer	0.00407	0.0131	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00376	0.0121	CcSEcCtD
Tolterodine—Chest pain—Teniposide—lymphatic system cancer	0.00357	0.0115	CcSEcCtD
Tolterodine—Urinary retention—Vincristine—lymphatic system cancer	0.00355	0.0114	CcSEcCtD
Tolterodine—Confusional state—Teniposide—lymphatic system cancer	0.00345	0.0111	CcSEcCtD
Tolterodine—Oedema—Teniposide—lymphatic system cancer	0.00342	0.011	CcSEcCtD
Tolterodine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00342	0.011	CcSEcCtD
Tolterodine—Infection—Teniposide—lymphatic system cancer	0.0034	0.0109	CcSEcCtD
Tolterodine—Tachycardia—Teniposide—lymphatic system cancer	0.00334	0.0108	CcSEcCtD
Tolterodine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00317	0.0102	CcSEcCtD
Tolterodine—Arthralgia—Fludarabine—lymphatic system cancer	0.00313	0.0101	CcSEcCtD
Tolterodine—Confusional state—Fludarabine—lymphatic system cancer	0.00303	0.00977	CcSEcCtD
Tolterodine—Dysuria—Vincristine—lymphatic system cancer	0.00302	0.00973	CcSEcCtD
Tolterodine—Oedema—Fludarabine—lymphatic system cancer	0.003	0.00969	CcSEcCtD
Tolterodine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.003	0.00969	CcSEcCtD
Tolterodine—Infection—Fludarabine—lymphatic system cancer	0.00298	0.00962	CcSEcCtD
Tolterodine—Urinary tract infection—Carmustine—lymphatic system cancer	0.00293	0.00945	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00292	0.00942	CcSEcCtD
Tolterodine—Flushing—Bleomycin—lymphatic system cancer	0.00288	0.00928	CcSEcCtD
Tolterodine—Weight increased—Mitoxantrone—lymphatic system cancer	0.00286	0.00922	CcSEcCtD
Tolterodine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00282	0.00908	CcSEcCtD
Tolterodine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00279	0.00901	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00274	0.00883	CcSEcCtD
Tolterodine—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00272	0.00878	CcSEcCtD
Tolterodine—Abdominal pain—Teniposide—lymphatic system cancer	0.0027	0.00871	CcSEcCtD
Tolterodine—Hallucination—Carmustine—lymphatic system cancer	0.00269	0.00868	CcSEcCtD
Tolterodine—Oedema peripheral—Carmustine—lymphatic system cancer	0.00267	0.0086	CcSEcCtD
Tolterodine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00264	0.00853	CcSEcCtD
Tolterodine—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00263	0.00848	CcSEcCtD
Tolterodine—Visual impairment—Carmustine—lymphatic system cancer	0.00261	0.00841	CcSEcCtD
Tolterodine—Fatigue—Fludarabine—lymphatic system cancer	0.00259	0.00835	CcSEcCtD
Tolterodine—Hallucination—Vincristine—lymphatic system cancer	0.00257	0.00829	CcSEcCtD
Tolterodine—Pain—Fludarabine—lymphatic system cancer	0.00257	0.00828	CcSEcCtD
Tolterodine—Constipation—Fludarabine—lymphatic system cancer	0.00257	0.00828	CcSEcCtD
Tolterodine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00252	0.00812	CcSEcCtD
Tolterodine—Flushing—Carmustine—lymphatic system cancer	0.00251	0.0081	CcSEcCtD
Tolterodine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00248	0.00798	CcSEcCtD
Tolterodine—Asthenia—Teniposide—lymphatic system cancer	0.00245	0.00791	CcSEcCtD
Tolterodine—Diarrhoea—Teniposide—lymphatic system cancer	0.00234	0.00754	CcSEcCtD
Tolterodine—Chest pain—Bleomycin—lymphatic system cancer	0.0023	0.00741	CcSEcCtD
Tolterodine—Confusional state—Bleomycin—lymphatic system cancer	0.00222	0.00716	CcSEcCtD
Tolterodine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00221	0.00714	CcSEcCtD
Tolterodine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0022	0.0071	CcSEcCtD
Tolterodine—Oedema—Bleomycin—lymphatic system cancer	0.0022	0.0071	CcSEcCtD
Tolterodine—Infection—Bleomycin—lymphatic system cancer	0.00219	0.00706	CcSEcCtD
Tolterodine—Asthenia—Fludarabine—lymphatic system cancer	0.00216	0.00695	CcSEcCtD
Tolterodine—Headache—Teniposide—lymphatic system cancer	0.00214	0.0069	CcSEcCtD
Tolterodine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00206	0.00663	CcSEcCtD
Tolterodine—Vertigo—Vincristine—lymphatic system cancer	0.00202	0.00651	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00201	0.00647	CcSEcCtD
Tolterodine—Chest pain—Carmustine—lymphatic system cancer	0.00201	0.00647	CcSEcCtD
Tolterodine—Anxiety—Carmustine—lymphatic system cancer	0.002	0.00644	CcSEcCtD
Tolterodine—Confusional state—Carmustine—lymphatic system cancer	0.00194	0.00625	CcSEcCtD
Tolterodine—Oedema—Carmustine—lymphatic system cancer	0.00192	0.0062	CcSEcCtD
Tolterodine—Infection—Carmustine—lymphatic system cancer	0.00191	0.00616	CcSEcCtD
Tolterodine—Pain—Bleomycin—lymphatic system cancer	0.00188	0.00607	CcSEcCtD
Tolterodine—Headache—Fludarabine—lymphatic system cancer	0.00188	0.00607	CcSEcCtD
Tolterodine—Tachycardia—Carmustine—lymphatic system cancer	0.00188	0.00605	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00187	0.00604	CcSEcCtD
Tolterodine—Chest pain—Mitoxantrone—lymphatic system cancer	0.00186	0.00601	CcSEcCtD
Tolterodine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00186	0.00601	CcSEcCtD
Tolterodine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00186	0.00599	CcSEcCtD
Tolterodine—Oedema—Vincristine—lymphatic system cancer	0.00184	0.00592	CcSEcCtD
Tolterodine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00184	0.00592	CcSEcCtD
Tolterodine—Infection—Vincristine—lymphatic system cancer	0.00182	0.00588	CcSEcCtD
Tolterodine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00182	0.00585	CcSEcCtD
Tolterodine—Confusional state—Mitoxantrone—lymphatic system cancer	0.0018	0.00581	CcSEcCtD
Tolterodine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00179	0.00576	CcSEcCtD
Tolterodine—Oedema—Mitoxantrone—lymphatic system cancer	0.00179	0.00576	CcSEcCtD
Tolterodine—Infection—Mitoxantrone—lymphatic system cancer	0.00178	0.00573	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00175	0.00565	CcSEcCtD
Tolterodine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00174	0.00562	CcSEcCtD
Tolterodine—Somnolence—Carmustine—lymphatic system cancer	0.00171	0.00551	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00167	0.00539	CcSEcCtD
Tolterodine—Constipation—Carmustine—lymphatic system cancer	0.00164	0.0053	CcSEcCtD
Tolterodine—Pain—Carmustine—lymphatic system cancer	0.00164	0.0053	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00163	0.00525	CcSEcCtD
Tolterodine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00162	0.00523	CcSEcCtD
Tolterodine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00159	0.00512	CcSEcCtD
Tolterodine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00158	0.00511	CcSEcCtD
Tolterodine—Fatigue—Vincristine—lymphatic system cancer	0.00158	0.0051	CcSEcCtD
Tolterodine—Asthenia—Bleomycin—lymphatic system cancer	0.00158	0.0051	CcSEcCtD
Tolterodine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00157	0.00507	CcSEcCtD
Tolterodine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00157	0.00507	CcSEcCtD
Tolterodine—Constipation—Vincristine—lymphatic system cancer	0.00157	0.00506	CcSEcCtD
Tolterodine—Pain—Vincristine—lymphatic system cancer	0.00157	0.00506	CcSEcCtD
Tolterodine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00154	0.00497	CcSEcCtD
Tolterodine—Pain—Mitoxantrone—lymphatic system cancer	0.00153	0.00493	CcSEcCtD
Tolterodine—Constipation—Mitoxantrone—lymphatic system cancer	0.00153	0.00493	CcSEcCtD
Tolterodine—Abdominal pain—Carmustine—lymphatic system cancer	0.00152	0.0049	CcSEcCtD
Tolterodine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.0015	0.00484	CcSEcCtD
Tolterodine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00147	0.00475	CcSEcCtD
Tolterodine—Dysuria—Methotrexate—lymphatic system cancer	0.00146	0.00472	CcSEcCtD
Tolterodine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00146	0.00471	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00146	0.00469	CcSEcCtD
Tolterodine—Abdominal pain—Vincristine—lymphatic system cancer	0.00145	0.00468	CcSEcCtD
Tolterodine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00142	0.00457	CcSEcCtD
Tolterodine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00141	0.00456	CcSEcCtD
Tolterodine—Asthenia—Carmustine—lymphatic system cancer	0.00138	0.00445	CcSEcCtD
Tolterodine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00135	0.00436	CcSEcCtD
Tolterodine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00132	0.00425	CcSEcCtD
Tolterodine—Asthenia—Vincristine—lymphatic system cancer	0.00132	0.00425	CcSEcCtD
Tolterodine—Diarrhoea—Carmustine—lymphatic system cancer	0.00132	0.00424	CcSEcCtD
Tolterodine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00128	0.00414	CcSEcCtD
Tolterodine—Dizziness—Carmustine—lymphatic system cancer	0.00127	0.0041	CcSEcCtD
Tolterodine—Diarrhoea—Vincristine—lymphatic system cancer	0.00126	0.00405	CcSEcCtD
Tolterodine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00122	0.00394	CcSEcCtD
Tolterodine—Dizziness—Vincristine—lymphatic system cancer	0.00121	0.00391	CcSEcCtD
Tolterodine—Visual impairment—Methotrexate—lymphatic system cancer	0.00121	0.00389	CcSEcCtD
Tolterodine—Headache—Carmustine—lymphatic system cancer	0.0012	0.00388	CcSEcCtD
Tolterodine—Headache—Vincristine—lymphatic system cancer	0.00115	0.00371	CcSEcCtD
Tolterodine—Headache—Mitoxantrone—lymphatic system cancer	0.00112	0.00361	CcSEcCtD
Tolterodine—Vertigo—Methotrexate—lymphatic system cancer	0.00098	0.00316	CcSEcCtD
Tolterodine—Chest pain—Methotrexate—lymphatic system cancer	0.000929	0.003	CcSEcCtD
Tolterodine—Arthralgia—Methotrexate—lymphatic system cancer	0.000929	0.003	CcSEcCtD
Tolterodine—Confusional state—Methotrexate—lymphatic system cancer	0.000898	0.0029	CcSEcCtD
Tolterodine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000891	0.00287	CcSEcCtD
Tolterodine—Infection—Methotrexate—lymphatic system cancer	0.000885	0.00285	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000811	0.00262	CcSEcCtD
Tolterodine—Somnolence—Methotrexate—lymphatic system cancer	0.000792	0.00255	CcSEcCtD
Tolterodine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000784	0.00253	CcSEcCtD
Tolterodine—Fatigue—Methotrexate—lymphatic system cancer	0.000768	0.00248	CcSEcCtD
Tolterodine—Pain—Methotrexate—lymphatic system cancer	0.000762	0.00246	CcSEcCtD
Tolterodine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000734	0.00237	CcSEcCtD
Tolterodine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000728	0.00235	CcSEcCtD
Tolterodine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000704	0.00227	CcSEcCtD
Tolterodine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000656	0.00212	CcSEcCtD
Tolterodine—Asthenia—Methotrexate—lymphatic system cancer	0.000639	0.00206	CcSEcCtD
Tolterodine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000609	0.00196	CcSEcCtD
Tolterodine—Dizziness—Methotrexate—lymphatic system cancer	0.000589	0.0019	CcSEcCtD
Tolterodine—Headache—Methotrexate—lymphatic system cancer	0.000558	0.0018	CcSEcCtD
